What is Vect-Horus?
Vect-Horus operates at the intersection of advanced pharmacology and molecular engineering, specializing in the development of innovative targeting technology. The company is primarily focused on enhancing the systemic delivery of therapeutic and imaging agents, with a specific emphasis on RNA-targeted medicines for complex neurological diseases. By optimizing the transport of these agents to specific organs and tumors, Vect-Horus addresses critical bottlenecks in central nervous system therapies.
The company's market position is bolstered by strategic collaborations with major pharmaceutical entities, which validate its technological platform. Through its commitment to research excellence and collaborative innovation, Vect-Horus is positioning itself as a key player in the next generation of precision medicine, aiming to improve patient outcomes through superior drug delivery mechanisms.
How much funding has Vect-Horus raised?
Vect-Horus has raised a total of $31.4M across 5 funding rounds:
Angel/Seed
$1.8M
Series A
$3M
Series B
$4.2M
Series C
$7.9M
Series D
$14.5M
Angel/Seed (2014): $1.8M, investors not publicly disclosed
Series A (2017): $3M, investors not publicly disclosed
Series B (2018): $4.2M supported by CAAP Creation, Financiere Tuileries Co-Invest, and SCR Provencale et Corse
Series C (2020): $7.9M, investors not publicly disclosed
Series D (2021): $14.5M, investors not publicly disclosed
Key Investors in Vect-Horus
CAAP Creation
A venture capital firm focused on supporting innovative startups and regional economic development through strategic equity investments.
Financiere Tuileries Co-Invest
An investment vehicle specializing in co-investment opportunities for high-growth companies within the European technology and life sciences sectors.
SCR Provencale et Corse
A regional investment firm providing capital and strategic guidance to emerging enterprises to foster industrial and technological growth.
What's next for Vect-Horus?
With the recent infusion of capital, Vect-Horus is well-positioned to accelerate its clinical pipeline and expand its research capabilities. The company is expected to prioritize the advancement of its RNA-targeted medicine programs, moving closer to potential commercialization milestones. Future strategic efforts will likely focus on deepening existing pharmaceutical partnerships and exploring new therapeutic applications for its proprietary delivery platform.
As the company transitions into its next phase of growth, the focus will remain on scaling its operational infrastructure to meet the demands of late-stage clinical trials. Investors and industry observers will be monitoring the firm's ability to translate its technological advancements into tangible clinical results, which will be pivotal for its long-term valuation and market influence.
